ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.303,28
0,00%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1742
0,06%
Bitcoin
70.043,46
2,24%
Brent Oil
82,845
1,06%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Retrophin Inc (RTRX)

  7. Retrophin Inc (RTRX) Notícias

RTRX

Retrophin (RTRX)

Retrophin Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RTRX
DataHoraFonteTítuloCódigoCompanhia
31/05/202317:58Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RTRXRetrophin Inc
19/05/202317:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RTRXRetrophin Inc
15/05/202318:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:RTRXRetrophin Inc
10/05/202313:59Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:RTRXRetrophin Inc
04/05/202317:48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RTRXRetrophin Inc
13/04/202318:13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RTRXRetrophin Inc
23/02/202319:04Edgar (US Regulatory)Annual Report (10-k)NASDAQ:RTRXRetrophin Inc
06/02/202316:56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RTRXRetrophin Inc
01/09/202219:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:RTRXRetrophin Inc
18/08/202217:07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:RTRXRetrophin Inc
17/08/202218:22Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:RTRXRetrophin Inc
09/03/202208:05Edgar (US Regulatory)Initial Statement of Trust Indenture (305b2)NASDAQ:RTRXRetrophin Inc
09/03/202208:04Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:RTRXRetrophin Inc
23/11/202116:58Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:RTRXRetrophin Inc
03/09/202117:21Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:RTRXRetrophin Inc
12/02/202119:10Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:RTRXRetrophin Inc
30/11/202018:05GlobeNewswire Inc.Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmen...NASDAQ:RTRXRetrophin Inc
16/11/202010:00GlobeNewswire Inc.Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.NASDAQ:RTRXRetrophin Inc
12/11/202018:05GlobeNewswire Inc.Retrophin Completes Acquisition of Orphan TechnologiesNASDAQ:RTRXRetrophin Inc
11/11/202018:30GlobeNewswire Inc.Retrophin to Present at Upcoming Investor ConferencesNASDAQ:RTRXRetrophin Inc
05/11/202018:01GlobeNewswire Inc.Retrophin Reports Third Quarter 2020 Financial ResultsNASDAQ:RTRXRetrophin Inc
22/10/202017:01GlobeNewswire Inc.Retrophin Announces Agreement to Acquire Orphan TechnologiesNASDAQ:RTRXRetrophin Inc
21/10/202017:30GlobeNewswire Inc.Retrophin to Report Third Quarter 2020 Financial ResultsNASDAQ:RTRXRetrophin Inc
14/10/202018:00GlobeNewswire Inc.Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RTRXRetrophin Inc
09/10/202017:01GlobeNewswire Inc.Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 ReimaginedNASDAQ:RTRXRetrophin Inc
21/09/202009:00GlobeNewswire Inc.Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA NephropathyNASDAQ:RTRXRetrophin Inc
30/07/202017:01GlobeNewswire Inc.Retrophin Reports Second Quarter 2020 Financial ResultsNASDAQ:RTRXRetrophin Inc
16/07/202017:30GlobeNewswire Inc.Retrophin to Report Second Quarter 2020 Financial ResultsNASDAQ:RTRXRetrophin Inc
19/06/202009:00GlobeNewswire Inc.Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare ConferenceNASDAQ:RTRXRetrophin Inc
08/06/202023:02GlobeNewswire Inc.Retrophin Announces Pricing of Public Offering of Common StockNASDAQ:RTRXRetrophin Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RTRX

Seu Histórico Recente

ASX
MRF
BIT
F37298
Vontobel Financial Produ...
NASDAQ
HOBAX
Holbrook Income Fund Cla...
NYSE
SCX
LS Starrett
AMEX
IXJ
iShares Global Healthcare
BIT
UB7DK2
Unicredit Bank
COIN
EGOUSD
LATK
MTWPUSDT
MetaWhale
XE
0GZJ
BNP Paribas Arbitrage Is...
ASX
CIMKOT
BIT
UB891D
Unicredit Bank
COIN
ETYUST
Ethereum Cloud
EU
LIAT
Klepierre 1.25% 29sep2031
BIT
F34599
Vontobel Financial Produ...
COIN
HAKAUST
TribeOne
USOTC
ENDPQ
Endo (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados